Your SlideShare is downloading. ×
  • Like
  • Save
Lung Cancer Stages, Treatments and Targeted Therapies - David Barbie, MD
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Lung Cancer Stages, Treatments and Targeted Therapies - David Barbie, MD

  • 2,804 views
Published

Audio and slides for this presentation are available on YouTube: http://youtu.be/rt_O7m2eTYA …

Audio and slides for this presentation are available on YouTube: http://youtu.be/rt_O7m2eTYA

David Barbie, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, discusses the stages of lung cancer, how the disease is treated, and new targeted therapies for patients. This presentation was originally given at Dana-Farber's "Living with Lung Cancer" forum on Nov. 2, 2013.

Published in Health & Medicine
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
2,804
On SlideShare
0
From Embeds
0
Number of Embeds
2

Actions

Shares
Downloads
1
Comments
0
Likes
3

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Lung Cancer: Stages, Treatments and Targeted Therapies David Barbie, M.D. Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute Assistant Professor of Medicine, Harvard Medical School November 2, 2013
  • 2. Lung Cancer Incidence and Mortality in U.S. KRAS Mutation ~30% ~50% ~90%
  • 3. Lung Cancer Stages and Treatments
  • 4. Lung Cancer Stages and Treatments Stage 1: Localized
  • 5. Lung Cancer Stages and Treatments Stage 1: Localized Stage 2: Larger (> 5 cm) or spread to local lymph nodes Surgery, +/-chemotherapy
  • 6. Lung Cancer Stages and Treatments Stage 1: Localized Stage 2: Larger (> 5 cm) or spread to local lymph nodes Surgery, +/-chemotherapy Stage 3: Locally advanced Chemotherapy and radiation, +/- surgery
  • 7. Lung Cancer Stages and Treatments Stage 1: Localized Stage 2: Larger (> 5 cm) or spread to local lymph nodes Brain Surgery, +/-chemotherapy Stage 3: Locally advanced Chemotherapy and radiation, +/- surgery Bone Stage 4: Advanced/metastatic Chemotherapy +/- palliative radiation Liver Adrenals
  • 8. Oncogenes are the Jammed Accelerators of Cancer Cells
  • 9. BCR-ABL - BCR-ABL + Shtivelman et al. Nature 1985;315:550 Daley et al. Science 1990;247:824 Buchdunger et al. Cancer Res 1996;56:100 Deininger et al. Blood 1997;90:3691 Druker, BJ. Nat Med 2009;15:1149
  • 10. Lynch et al. NEJM 2004;350:2129 Paez et al. Science 2004;304:1497
  • 11. Mok et al. NEJM 2009;361:947
  • 12. Better than chemotherapy, but tumors become resistant after 10-12 months Mok et al. NEJM 2009;361:947
  • 13. Genomic complexity of lung cancer CML Lung Adenocarcinoma http://www.path.cam.ac.uk http://www.utoronto.ca/cancyto
  • 14. Lung Cancer Then and Now Many different oncogenes can get jammed No known genotype 1984 - 2003 No known genotype 2004 Erlotinib X X 2009 Crizotinib 2012 Courtesy of Stephanie Cardarella, MD, DFCI Thoracic Oncology
  • 15. Chemotherapy Targets the Engine, Targeted Therapy the Accelerator EGFR inhibitor ALK inhibitor BRAF inhibitor Carboplatin + Alimta or Taxol
  • 16. DFCI Patient with NSCLC and BRAF mutation treated with Dabrafenib August 10, 2012 September 19, 2012 Courtesy of Stephanie Cardarella, MD, DFCI Thoracic Oncology
  • 17. MSKCC Patient with NSCLC and BRAF mutation treated with Dabrafenib February 2012 June 2012 Courtesy of Gregory Riely, MD, Memorial Sloan-Kettering Cancer Center
  • 18. KRAS is Difficult To Target Directly KRAS inhibitor – failed clinical trials
  • 19. Alternatives to Targeting KRAS 1. Block known downstream pathways (between pedal and engine) Also failing in clinical trials
  • 20. Alternatives to Targeting KRAS 1. Block known downstream pathways (between pedal and engine) XX Also failing in clinical trials X X
  • 21. Alternatives to Targeting KRAS 2. Use genomics to identify currently unknown pathways needed for survival (that keep car from crashing) TBK1
  • 22. CYT387 Impairs Viability of Lung cancer Cells A549 Lung Cancer Cells DMSO CYT387 (5mM)
  • 23. Activity of CYT387 in Kras-driven Murine Lung Cancer Murine KRAS-Driven Lung Cancer CYT387 100mg/kg/d H Baseline H Week 16 Kwok Wong Travis Cohoon
  • 24. Activity of CYT387 in Kras-driven Murine Lung Cancer H E pA ST T3 A B Uee n ad t t r 2m 5 µ C 2m 5 µ D Tor an a t el e xe o 2m 5 µ E 2m 5 µ F C an Yl e To 2m 5 µ 2m 5 µ
  • 25. Alternatives to Targeting KRAS Blocking multiple unique pathways
  • 26. Alternatives to Targeting KRAS Blocking multiple unique pathways X X X X
  • 27. Activity of CYT387 in Kras-driven Murine Lung Cancer KrasLSL-G12D/WT;p53flox/flox model with established tumor burden *p<0.01 **p<0.0001 CYT387: 100 mg/kg/daily by oral gavage Selumetinib: 25 mg/kg/twice daily by oral gavage Kwok Wong Travis Cohoon
  • 28. Activity of CYT387 in Kras-driven Murine Lung Cancer KrasLSL-G12D/WT;p53flox/flox model with established tumor burden *p<0.01 **p<0.0001 Treatment well tolerated other than initial gavage trauma CYT387: 100 mg/kg/daily by oral gavage Selumetinib: 25 mg/kg/twice daily by oral gavage Kwok Wong Travis Cohoon
  • 29. Immunotherapy – “Immune Checkpoint Blockade”
  • 30. Immunotherapy – “Immune Checkpoint Blockade”
  • 31. Immunotherapy – “Immune Checkpoint Blockade” PD-L1 PD-L1 PD-L1
  • 32. Immunotherapy – “Immune Checkpoint Blockade” T cell T cell PD1 PD1 PD-L1 PD-L1 PD-L1 PD1 T cell
  • 33. Immunotherapy – “Immune Checkpoint Blockade” T cell X T cell PD1 X PD1 PD-L1 PD-L1 PD-L1 T cell X PD1
  • 34. Immunotherapy – “Immune Checkpoint Blockade” T cell PD-L1 targeted drugs T cell X PD1 X PD1 PD-L1 PD-L1 PD-L1 T cell X PD1
  • 35. Immunotherapy – “Immune Checkpoint Blockade” T cell T cell PD1 PD1 PD1 T cell
  • 36. Immunotherapy – “Immune Checkpoint Blockade” T cell T cell PD1 PD1 PD1 T cell
  • 37. Summary • Lung cancer can be treated with a combination of surgery, radiation, and chemotherapy depending on the stage
  • 38. Summary • Lung cancer can be treated with a combination of surgery, radiation, and chemotherapy depending on the stage • We continue to develop new ways to target lung cancer more directly, with increasing success
  • 39. Summary • Lung cancer can be treated with a combination of surgery, radiation, and chemotherapy depending on the stage • We continue to develop new ways to target lung cancer more directly, with increasing success • With combinations of these new targeted therapies the future is very bright